Eff ect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis ( MS-STAT ) : a randomised , placebo-controlled , phase 2 trial

Chataway, Jeremy; Schuerer, Nadine; Alsanousi, Ali; Chan, Dennis; MacManus, David; Hunter, Kelvin; Anderson, Val; Bangham, Charles RM; Clegg, Shona; Nielsen, Casper; +7 more... Fox, Nick C; Wilkie, David; Nicholas, Jennifer M; Calder, Virginia L; Greenwood, John; Frost, Chris; Nicholas, Richard; (2014) Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet, 383 (9936). pp. 2213-2221. ISSN 0140-6736 DOI: https://doi.org/10.1016/S0140-6736(13)62242-4 Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/1621694/

[1]  J. Hobart,et al.  Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial , 2013, The Lancet Neurology.

[2]  Hans Lassmann,et al.  Progressive multiple sclerosis: pathology and pathogenesis , 2012, Nature Reviews Neurology.

[3]  C Confavreux,et al.  Reliability of Longitudinal Brain Volume Loss Measurements between 2 Sites in Patients with Multiple Sclerosis: Comparison of 7 Quantification Techniques , 2012, American Journal of Neuroradiology.

[4]  M. Rovaris,et al.  Interferon β for secondary progressive multiple sclerosis: a systematic review , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[5]  D. Sobieraj,et al.  Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[6]  R. Marshall,et al.  Statins and Cerebral Hemodynamics , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  J. Slotboom,et al.  Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial , 2012, Journal of Neurology.

[8]  Jeffrey A Cohen,et al.  Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects , 2012, The Lancet Neurology.

[9]  C. Humphries.  Progressive multiple sclerosis: The treatment gap , 2012, Nature.

[10]  A. Cross,et al.  Randomized controlled trial of atorvastatin in clinically isolated syndrome , 2012, Neurology.

[11]  H. Larsson,et al.  Simvastatin improves final visual outcome in acute optic neuritis: a randomized study , 2012, Multiple sclerosis.

[12]  Hongye Luo,et al.  Statins for multiple sclerosis. , 2011, The Cochrane database of systematic reviews.

[13]  A. Traboulsee,et al.  A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS , 2011, Neurology.

[14]  P. Sørensen,et al.  Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial , 2011, The Lancet Neurology.

[15]  R. Reynolds,et al.  The neuropathological basis of clinical progression in multiple sclerosis , 2011, Acta Neuropathologica.

[16]  David H. Miller,et al.  Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial , 2010, The Lancet Neurology.

[17]  M. Battaglini,et al.  Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes , 2010, Neurology.

[18]  M. Sahraian,et al.  Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial , 2010, Multiple sclerosis.

[19]  Michael Weiner,et al.  Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection , 2010, NeuroImage.

[20]  R. Marrie,et al.  Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis , 2010, Neurology.

[21]  G. Tedeschi,et al.  Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing— remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy , 2010, Multiple sclerosis.

[22]  World Medical Association (WMA),et al.  Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects , 2009, Journal of the Indian Medical Association.

[23]  V. Morra,et al.  COMBINING BETA INTERFERON AND ATORVASTATIN MAY INCREASE DISEASE ACTIVITY IN MULTIPLE SCLEROSIS , 2009, Neurology.

[24]  David H. Miller,et al.  Imaging outcomes for neuroprotection and repair in multiple sclerosis trials , 2009, Nature Reviews Neurology.

[25]  A. Dolga,et al.  Statins: Mechanisms of neuroprotection , 2009, Progress in Neurobiology.

[26]  Chris Frost,et al.  Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run‐in period increase efficiency? , 2008, Statistics in medicine.

[27]  M. Filippi,et al.  Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis , 2008, Neurology.

[28]  Nick C. Fox,et al.  Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: Cross-validation of BSI, SIENA and SIENAX , 2007, NeuroImage.

[29]  J. Greenwood,et al.  Statins and the vascular endothelial inflammatory response. , 2007, Trends in immunology.

[30]  Chris Frost,et al.  Cerebral Atrophy Measurement in Clinically Isolated Syndromes and Relapsing Remitting Multiple Sclerosis: A Comparison of Registration‐Based Methods , 2007, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[31]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[32]  S. Youssef,et al.  Statins in the treatment of central nervous system autoimmune disease , 2006, Journal of Neuroimmunology.

[33]  Lawrence Steinman,et al.  Statin therapy and autoimmune disease: from protein prenylation to immunomodulation , 2006, Nature Reviews Immunology.

[34]  M. Rovaris,et al.  Secondary progressive multiple sclerosis: current knowledge and future challenges , 2006, The Lancet Neurology.

[35]  S. Isenmann,et al.  Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins. , 2006, Restorative neurology and neuroscience.

[36]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[37]  S. Lightman,et al.  Intracellular T lymphocyte cytokine profiles in the aqueous humour of patients with uveitis and correlation with clinical phenotype , 2005, Clinical and experimental immunology.

[38]  Chris Frost,et al.  The analysis of repeated ‘direct’ measures of change illustrated with an application in longitudinal imaging , 2004, Statistics in medicine.

[39]  V. Durkalski,et al.  Oral simvastatin treatment in relapsing-remitting multiple sclerosis , 2004, The Lancet.

[40]  Nicole A. Lazar,et al.  Statistical Analysis With Missing Data , 2003, Technometrics.

[41]  P. Adamson,et al.  Lovastatin inhibits brain endothelial cell Rho‐mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  J H Simon,et al.  Eight-year follow-up study of brain atrophy in patients with MS , 2002, Neurology.

[43]  L. Steinman,et al.  Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. , 2002, Neurology.

[44]  A Thompson,et al.  The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. , 2001, Brain : a journal of neurology.

[45]  J. Hobart,et al.  Kurtzke scales revisited: the application of psychometric methods to clinical intuition. , 2000, Brain : a journal of neurology.

[46]  Stephen M. Rao,et al.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.

[47]  M. Moskowitz,et al.  Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[49]  Anthony C. Davison,et al.  Bootstrap Methods and Their Application , 1998 .

[50]  Nick C. Fox,et al.  The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI , 1997, IEEE Transactions on Medical Imaging.

[51]  S. Senn,et al.  Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. , 1994, Statistics in medicine.

[52]  T. A. S. Group.  The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis , 1991, The Lancet.

[53]  N. Breslow.  Extra‐Poisson Variation in Log‐Linear Models , 1984 .

[54]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[55]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[56]  D. Shen,et al.  Ensemble sparse classification of Alzheimer's disease , 2012, NeuroImage.